>100 Scientific Articles Published
Results from multiple randomized clinical trials of the Zephyr® Valve have demonstrated clinically meaningful benefits in lung function, exercise capacity, and quality of life (QoL).1-5
Consistent Clinical Findings Across Four Randomized Controlled Trials
FEV1 Percent Change
from Baseline to 12 Months
Published in The American Journal of Respiratory and Critical Care Medicine1
The benefits are comparable to those seen with LVRS (lung volume reduction surgery) but with a reduction in post-procedure morbidity.”
- Multicenter, multinational, randomized controlled trial
- Results out to 12 months
- Heterogeneous emphysema with little to no collateral ventilation
- Clinically meaningful and statistically significant benefits over current standard of care medical therapy
- Improvements in:
- Lung function
- Exercise tolerance
- Dyspnea
- Quality of life
Published in The American Journal of Respiratory and Critical Care Medicine2
Benefits are in line with those seen with LVRS (lung volume reduction surgery), and the consistent trial results, potential reduction in post-procedure morbidity, and reversibility of the procedure position Zephyr treatment as a viable treatment option in those who remain symptomatic on maximal medical therapy.”
- Multicenter, multinational, randomized controlled trial
- Heterogeneous emphysema with little or no collateral ventilation
- Clinically meaningful and statistically significant benefits over current standard of care medical therapy
- Improvements in:
- Lung function
- Exercise tolerance
- Dyspnea
- Quality of life
FEV1 Percent Change
from Baseline to 6 Months
FEV1 Percent Change
from Baseline to 6 Months
Published in The American Journal of Respiratory and Critical Care Medicine3
EBV therapy in selected patients with homogeneous emphysema without collateral ventilation results in clinically meaningful benefits of improved lung function, exercise tolerance, and quality of life. Given the very limited treatment options available for this patient population, EBV therapy should be considered in these patients.”
- Prospective randomized controlled trial
- Homogeneous emphysema with little or no collateral ventilation
- Clinically meaningful benefits in:
- Lung function
- Exercise tolerance
- Quality of life
Published in The New England Journal of Medicine4
Endobronchial valve treatment in patients with emphysema and a proven absence of interlobar collateral ventilation provided a measurable clinical benefit, with significantly improved lung function, exercise capacity, and quality of life as compared with usual care.”
- Prospective randomized controlled trial
- First randomized study to use Chartis® to pre-select candidates
- Emphysema with little or no collateral ventilation
- Statistically and clinically greater improvements than the control group for:
- Pulmonary function (FEV1 and FVC)
- Exercise capacity
- Quality of life
- One-year follow-up published in The American Journal of Respiratory and Critical Care Medicine5
FEV1 Percent Change
from Baseline to 6 Months
International Guidance Documents Include Endobronchial Valve Treatment as an Option for Emphysema Patients
Multiple independent networks have concluded that with proper patient selection, the Zephyr Valve procedure should be considered in the treatment of severe emphysema.
The quality of evidence for treatment with endobronchial valves has been graded “A” by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).10
The United Kingdom’s National Institute for Health and Care Excellence (NICE) has included this treatment as part of standard measures for COPD and recommended all qualifying patients be evaluated for eligibility.11,34
Patient Treatment Preference
A detailed survey of 294 severe emphysema patients evaluated how they balance potential risks and benefits. The study concluded that patients with severe emphysema value access to an interventional treatment that offers benefits above and beyond their current medical management, despite the risks associated with these treatments.8
